Incyte (INCY) Competitors

Alnylam Pharmaceuticals (NASDAQ:ALNY) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, community ranking, earnings, risk, institutional ownership, profitability and dividends.

Do institutionals & insiders believe in ALNY or INCY?

93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 17.6% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Which has preferable valuation and earnings, ALNY or INCY?

Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alnylam Pharmaceuticals	$2.25B	13.28	-$278.16M	-$2.17	-105.80
Incyte	$4.24B	2.67	$32.62M	$0.27	216.84

Does the media prefer ALNY or INCY?

In the previous week, Incyte had 4 more articles in the media than Alnylam Pharmaceuticals. MarketBeat recorded 28 mentions for Incyte and 24 mentions for Alnylam Pharmaceuticals. Incyte's average media sentiment score of 0.92 beat Alnylam Pharmaceuticals' score of 0.84 indicating that Incyte is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alnylam Pharmaceuticals	13 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Positive
Incyte	18 Very Positive mention(s)	5 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more risk and volatility, ALNY or INCY?

Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.

Do analysts rate ALNY or INCY?

Alnylam Pharmaceuticals presently has a consensus price target of $315.58, indicating a potential upside of 37.46%. Incyte has a consensus price target of $74.88, indicating a potential upside of 27.89%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher probable upside, research analysts plainly believe Alnylam Pharmaceuticals is more favorable than Incyte.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alnylam Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.77
Incyte	1 Sell rating(s)	13 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.21

Does the MarketBeat Community believe in ALNY or INCY?

Incyte received 63 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.31% of users gave Alnylam Pharmaceuticals an outperform vote while only 72.33% of users gave Incyte an outperform vote.

Company	Underperform	Outperform
Alnylam Pharmaceuticals	Outperform Votes 1163 76.31%	Underperform Votes 361 23.69%
Incyte	Outperform Votes 1226 72.33%	Underperform Votes 469 27.67%

Is ALNY or INCY more profitable?

Incyte has a net margin of 0.77% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Incyte's return on equity of 0.05% beat Alnylam Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alnylam Pharmaceuticals	-12.37%	N/A	-6.83%
Incyte	0.77%	0.05%	0.04%

Summary

Incyte beats Alnylam Pharmaceuticals on 13 of the 18 factors compared between the two stocks.